The Cooper Companies, Inc. (NASDAQ:COO) shares fell 15.96% in after-hours trading Wednesday after the company reported fiscal third-quarter results, announced the completion of its strategic review, and issued fiscal fourth-quarter and full-year guidance.

The stock closed Wednesday’s regular session down 6.22% at $63.48. It then fell 15.96% to $53.35 in after-hours trading.

Cooper Companies is a global medical device company operating through two business units: CooperVision, focused on contact lenses, and CooperSurgical, focused on fertility and women’s healthcare.

Third Quarter Fiscal 2026

Revenue rose 1% year over year to $1.066 billion. Non-GAAP diluted EPS came in at $1.15, up 4% from a year ago. CooperVision revenue was flat, with Americas sales down 2% and Asia Pacific down 5% organically. CEO Al White said reduced U.S. channel inventory weighed on results and is expected to continue impacting the fourth quarter. CooperSurgical revenue grew 3% organically.

Fourth Quarter and Fiscal 2026 Guidance

Cooper Companies expects fourth-quarter revenue of $1.057 billion to $1.080 billion and non-GAAP diluted EPS of $1.05 to $1.09. For full fiscal 2026, the company expects revenue of $4.229 billion to $4.252 billion and non-GAAP diluted EPS of $4.51 to $4.55.

Strategic Review

The company completed its strategic review, first announced in December 2025, during which the Board evaluated a possible sale of CooperSurgical. The Board unanimously concluded that shareholders would be better served by retaining CooperSurgical rather than pursuing a transaction. The Board also approved expanding its share repurchase authorization from $2 billion to $3 billion.

Trading Metrics

Cooper Companies has a market capitalization of $12.38 billion.

The stock has a 52-week high of $89.83 and a 52-week low of $58.89.

Cooper Companies shares are down 6.18% over the past year.

Benzinga’s Edge Stock Rankings show a negative price trend across the short-, medium- and long-term time frames.

Disclaimer: This content was produced with the help of AI tools and was reviewed and published by Benzinga editors.

Photo: Who is Danny / Shutterstock

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.